The PathHunter PD1 Signaling Bioassay consists of human cells engineered to stably express an ED-tagged immune checkpoint receptor, PD-1, while EA is fused to either the full length or the phosphotyrosine-binding SH2 domain of an intracellular signaling protein, SHP1. Engagement of the receptor by its ligand, or agonist antibodies results in phosphorylation of the receptor’s cytosolic tail. The SH2-domain fused to EA binds the phosphorylated receptor, forcing complementation of ED and EA, resulting in formation of an active β-gal enzyme, which hydrolyzes the substrate to generate a chemiluminescent signal.The bioassay kit contains all reagents needed for the assay including pre-qualified cryopreserved cells, detection reagents, cell plating reagent, positive control agonist, and assay plates.
Target/Description
Programmed cell death protein 1
Group
T cell receptor (inhibitory)
SH2 Domain
SHP1
Cell Background
Jurkat
Species
Human
Accession Number
NM_005018.2
Agonist/Ligand
Anti-PD1 Antibody [NAT105]
Antagonist/Inhibitor
Anti-PD1 antibody [NAT105]
Assay Measures
SH2 Recruitment
Bioassay Target Name
PD-1
Assay Qualified With
Keytruda®
Drug Trademark Owner
Keytruda®is a registered trademark of Merck & Co., Inc.